Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Summary not available.
Summary not available.
Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The management presentation is scheduled for Thursday, April 20th, at 1:30 p.m. ET (10:30 a.m. PT). Interested parties can access the live and archived webcast through the company's investor relations website.
Absci specializes in combining AI with scalable wet lab technologies to enhance drug development, aiming to accelerate time to clinic and improve success rates. Its Integrated Drug Creation™ platform allows rapid screening and validation of drug candidates. The company is headquartered in Vancouver, WA, with additional facilities in New York and Zug, Switzerland.
Absci Corporation (Nasdaq: ABSI) has partnered with M2GEN to leverage its generative AI platform and M2GEN's clinicogenomic database to accelerate the creation of new cancer treatments. This collaboration aims to streamline the drug discovery process, utilizing M2GEN's ORIEN AVATAR® data to identify specific antigens for immunotherapies. Absci's Integrated Drug Creation™ platform can reduce the time from AI-designed antibodies to lab-validated candidates to as little as six weeks. With over 360,000 patients enrolled in M2GEN's Total Cancer Care® protocol, this partnership seeks to revolutionize personalized medicine in oncology.
Absci Corporation (Nasdaq: ABSI) reported transformative results for 2022, achieving industry breakthroughs in drug development using generative AI. Key highlights include:
- Revenue rose to $5.7 million from $4.8 million year-over-year.
- R&D expenses increased to $58.9 million, reflecting enhanced platform capabilities.
- Net loss reduced to $104.9 million from $101.0 million.
- Cash reserves as of December 31, 2022, totaled $164.4 million.
Looking forward, Absci expects to add at least ten new active programs in 2023, enhancing its partnerships and cash flow.
Absci Corporation (Nasdaq: ABSI) announced its participation in the B. Riley Securities' Life Sciences Tools Conference on April 6, 2023. The event focuses on integrating AI and proteomics into drug discovery. Absci’s management will engage in a panel discussion at 7:30 a.m. PT and a fireside chat at 12:30 p.m. PT. Interested parties can access the live webcast by registering through the conference's website. Absci specializes in generative AI drug creation, aiming to expedite the development of biologics and enhance therapeutic benefits through its Integrated Drug Creation™ platform.
Absci Corporation (Nasdaq: ABSI) recently announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum scheduled for March 21, 2023, at 3:00 p.m. Eastern Time. This virtual event will feature a fireside chat with Absci management, providing insights into the company's innovative generative AI drug creation technologies.
Absci leverages AI alongside advanced wet lab methods to accelerate drug development, enhancing the probability of success by optimizing various drug characteristics. Interested parties can stream the event live via the company's investor relations website.
Absci Corporation (Nasdaq: ABSI) has expanded into the European pharmaceutical market by launching its Innovation Center in Zug, Switzerland. This strategic move aims to enhance its R&D portfolio and drug development pipeline. The company has appointed two senior executives, Christine Lemke and Christian Stegmann, to spearhead its initiatives. Lemke brings extensive experience from major global biopharmaceutical companies, while Stegmann has a strong background in R&D leadership. The Zug Innovation Center positions Absci to leverage European biotech resources and talent, underscoring its commitment to delivering innovative therapies using generative AI.
Absci Corporation (Nasdaq: ABSI), a leader in generative AI drug creation, announced their participation in the 43rd Annual Cowen Health Care Conference. The management team will engage in a panel discussion on March 6 at 1:40 PM PT and a fireside chat on March 8 at 9:50 AM PT. Both sessions will be accessible via a live and archived webcast on the company’s investor relations website. Absci utilizes its Integrated Drug Creation™ platform to enhance drug development, allowing rapid transitions from AI-designed antibodies to lab-validated candidates within weeks. The company aims to revolutionize the delivery of therapeutics globally.
Absci Corporation (Nasdaq: ABSI) has partnered with St. John’s Cancer Institute (SJCI) to accelerate cancer therapy development.
This collaboration utilizes Absci’s Integrated Drug Creation platform and SJCI’s extensive cancer biospecimen database to streamline the identification of new therapeutic candidates.
The initial focus will be on urological and gastrointestinal cancers, aiming to significantly reduce the typical decade-long drug development timeline and high costs.
Experts from both organizations express optimism that this partnership will enhance the discovery of effective cancer treatments.